Abstract
BackgroundDiminished growth can be a consequence of juvenile idiopathic arthritis (JIA).[1] Growth hormone signals through a Janus kinase (JAK)2 tyrosine kinase-coupled receptor.[2] Tofacitinib, an oral JAK inhibitor approved for JIA,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
